NCT05279755View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 26, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

October 31, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

prosetin

oral solution

DRUG

placebo

oral solution

Trial Locations (4)

78217

COMPLETED

Worldwide Clinical Trials Early Phase Services, San Antonio

02114

RECRUITING

Massachusetts General Hospital, Boston

H3A 2B4

RECRUITING

The Neuro - Montréal Neurological Institute-Hospital, Montreal

3584 CX

RECRUITING

University Medical Center Utrecht, Utrecht

Sponsors

Lead Sponsor

ProJenX
All Listed Sponsors
collaborator

Congressionally Directed Medical Research Programs

FED

lead

ProJenX

INDUSTRY

NCT05279755 - A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS | Biotech Hunter | Biotech Hunter